Journal of Gastroenterology and Digestive Diseases

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +44-1647-403003

Research Article - Journal of Gastroenterology and Digestive Diseases (2018) Volume 3, Issue 3

Evaluation of Golgi protein 73 as a prognostic marker after loco-regional ablation of HCC in Hepatitis C cirrhotic patients.

Background & Aim: Hepatocellular carcinoma is a global health problem. Its diagnosis depends mainly on abdominal ultrasound and serum alpha-fetoprotein. Golgi protein 73 is a type II membrane protein upregulated in hepatocytes. Serum Golgi protein 73 could be a promising biomarker for diagnosis and prognosis of hepatocellular carcinoma. The aim was to assess serum Golgi protein 73 as a marker for follow up of hepatocellular carcinoma patients after either radiofrequency or microwave ablation in comparison to alpha-fetoprotein.

Methods: This study was performed on 80 subjects (60 chronic hepatitis C and liver cirhosis, and 20 controls). They were divided into three groups; Group I: included 30 patients with hepatocellular carcinoma, Group II: included 30 patients without hepatocellular carcinoma, and Group III: included 20 healthy individuals as control ones. Golgi protein 73 was measured in all subjects and followed up in group I one, 3, and 6 months after locoregional ablation.

Results: Both alpha-fetoprotein and Golgi protein 73 were significantly higher in group I than either group II or group III. Alpha-fetoprotein had a cut off value >20 ng/mL (sensitivity 86.67%, specificity 84%). Golgi protein 73 level Golgi protein 73 had a cut off value >79.2 ng/mL (sensitivity 96.67%, specificity 96%). Both markers were decreasing after ablation in different periods of follow up. Golgi protein 73 was correlated positively with alpha-fetoprotein, ALT, and AST.

Conclusion: Golgi protein 73 is a useful marker in diagnosis of hepatocellular carcinoma, also in follow up after locoregional therapy to detect early recurrence.

Author(s): Nahla Khalaf, Mahmoud El-Kadeem, Amany Abo Elenein, Gamal Kasem, Elsayed Wasfi

Abstract Full Text PDF